Media stories about Nektar Therapeutics (NASDAQ:NKTR) have trended somewhat positive on Friday, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Nektar Therapeutics earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.8020390132659 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment’s analysis:
- BRIEF-Nektar Therapeutics Says Received Notice Of Termination From Bayer Of Co-Development, License, Co-Promotion Agreement (NKTR) (markets.businessinsider.com)
- Nektar Therapeutics down 1% premarket after Bayer bails on agreement to develop inhaled amikacin (seekingalpha.com)
- ‘Notable Upside Options Positioning’ in Nektar Therapeutics (NKTR) Highlights ‘Speculative Bullish Bias’ Over the Next Month -Susquehanna (streetinsider.com)
- Investor’s Roundup (Risk Factors in Focus) – Nektar Therapeutics, (NASDAQ: NKTR) – Stock Watch (stocksnewstimes.com)
- Notable Runners of Sector: Nektar Therapeutics (NASDAQ:NKTR) – The Stock Street (press release) (thestreetpoint.com)
Shares of Nektar Therapeutics (NASDAQ NKTR) traded up $1.85 during trading hours on Friday, reaching $56.90. 3,711,627 shares of the company were exchanged, compared to its average volume of 1,710,505. Nektar Therapeutics has a 52 week low of $11.41 and a 52 week high of $57.83. The company has a quick ratio of 3.99, a current ratio of 4.14 and a debt-to-equity ratio of 2.91.
NKTR has been the subject of a number of research reports. Mizuho reiterated a “buy” rating and issued a $45.00 price target (up previously from $30.00) on shares of Nektar Therapeutics in a report on Wednesday, November 8th. Cowen initiated coverage on Nektar Therapeutics in a report on Tuesday, November 7th. They issued an “outperform” rating for the company. ValuEngine upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Canaccord Genuity Group boosted their price target on Nektar Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a report on Wednesday, November 15th. Finally, Jefferies Group reiterated a “buy” rating and issued a $35.00 price target on shares of Nektar Therapeutics in a report on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and twelve have issued a buy rating to the stock. Nektar Therapeutics has an average rating of “Buy” and an average price target of $35.58.
In other news, CEO Howard W. Robin sold 83,333 shares of the company’s stock in a transaction on Monday, October 9th. The stock was sold at an average price of $24.20, for a total transaction of $2,016,658.60. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO John Nicholson sold 15,910 shares of the company’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $37.78, for a total value of $601,079.80. Following the transaction, the chief operating officer now directly owns 249,066 shares in the company, valued at $9,409,713.48. The disclosure for this sale can be found here. Insiders sold 941,427 shares of company stock valued at $27,509,448 in the last three months. 6.10% of the stock is currently owned by insiders.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.